Current research on angiotensin II AT 1 -receptor antagonists (AIIRAs) and selected studies presented at the recent symposium held in Amsterdam, The Netherlands, on 6 June 1998, titled 'Angiotensin II Receptor Antagonists are NOT all the Same' are reviewed. AIIRAs offer a number of potential advantages over alternative antihypertensive agents acting via the renin-angiotensin-aldosterone system. They combine blood pressure-lowering effects at least equivalent to those of angiotensin-converting enzyme (ACE) inhibitors, coupled with placebolike tolerability. Candesartan cilexetil is a novel AIIRA that has demonstrated clinical efficacy superior to losartan, has a sustained duration of action over 24 hours (trough:peak ratio close to 100%) and is well tolerated Keywords: candesartan cilexetil; angiotensin II AT 1 -receptor antagonist; organ protection; review
Antihypertensive therapy
Non-peptide angiotensin II AT 1 -receptor antagonists (AIIRAs) are a new class of drugs that represent a major advance in therapeutics for the treatment of cardiovascular disease. Members of this new class have been proved effective in the treatment of hypertension and have recently also shown promise for the treatment of heart failure. AIIRAs attenuate the effects of angiotensin II by blocking its action, competitively or non-competitively, at the AT 1 receptor. This receptor subtype mediates the cardiovascular and metabolic activities of angiotensin II. 1 This mode of action contrasts with that of angiotensin-converting enzyme (ACE) inhibitors, which partially inhibit the conversion of angiotensin I to angiotensin II. One of the disadvantages of ACE inhibitors is that angiotensin II is also produced by non-ACE-dependent pathways, notably those involving chymase in the heart and other tissues. 2 The more specific mechanism of action of AIIRAs means that the actions of angiotensin II are completely blocked at the effector site, independently of the route of its production. Moreover, because ACE is identical to the enzyme kininase II, which inhibits bradykinin formation, AIIRAs avoid the bradykinin potentiation induced by ACE inhibitors and the in patients with essential hypertension. Candesartan cilexetil has a rapid onset of action (approximately 80% of total blood pressure reduction within the first 2 weeks) and dose-dependent effects on blood pressure, is comparable in efficacy to a number of classes of antihypertensives, and is effective in combination therapy (eg, with hydrochlorothiazide and amlodipine). This favourable profile may be due in part to the highly selective, tight binding to and slow dissociation of candesartan from the AT 1 receptor. Preliminary studies suggest that candesartan cilexetil also protects end organs (kidney, heart, vasculature, and brain) beyond blood pressure control. associated adverse consequences. 3 There is growing evidence from a wide variety of clinical trials that the AIIRAs are able to combine or even to exceed the considerable benefits of ACE inhibition with the added bonus of improved tolerability. With particular attention to candesartan cilexetil, this article gives an overview of the antihypertensive potential of AIIRAs reviewed in this supplement which summarises the recent symposium held in Amsterdam, The Netherlands, on 6 June 1998, titled 'Angiotensin II Receptor Antagonists are NOT all the Same'.
Criteria for selecting an antihypertensive agent
The main criteria that need to be considered in making choices between different antihypertensive agents, particularly in the context of the AIIRAs, are the following: (1) efficacy in lowering blood pressure; (2) onset and duration of action; (3) organ-protective effects; and (4) the side effects profile. The sustained efficacy of any new antihypertensive agent in lowering blood pressure over the full 24-h period is particularly important, since existing therapies have only achieved relatively small reductions, averaging approximately 7%, 4 which equate to only a small reduction in risk. This outcome for hypertension management compares unfavourably with the situation for cardiovascular disease in general, where the 40% reduction in plasma cholesterol levels now attainable with some statins 5 represents a very considerable reduction of risk for ischaemic heart disease. The organ-protective effects of antihy-
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pertensive agents, as demonstrated with ACE inhibitors, are of special interest, since they offer opportunities for preventing the long-term progression of hypertension. A major problem with many contemporary treatments is poor compliance that mainly results from intolerance and efficacy deficiencies of many currently available agents.
Candesartan cilexetil-a novel angiotensin II AT 1 -receptor antagonist

Pharmacology
Candesartan cilexetil is a new, once-daily oral antihypertensive, which is completely hydrolysed during gastrointestinal absorption to the only active compound, candesartan, a potent, long-acting AIIRA selective for the type 1 receptor subtype. 6, 7 The pharmacokinetics of candesartan cilexetil are not affected by administration in the presence of food, 8 which simplifies treatment, and no clinically significant drug-drug interactions have been reported. 9 The pharmacology of angiotensin II receptors and AT 1 -receptor blockers, including candesartan cilexetil, is reviewed in this supplement by Dr Oliver Chung and colleagues from the Institute of Pharmacology, Christian-Albrechts-University, Kiel, Germany. It is now known that drugs like ACE inhibitors or angiotensin AT 1 -receptor antagonists can exert further beneficial actions independent of a reduction in blood pressure. Dr Chung et al's study reviews the literature, and reports on a reduction in vascular-and post-myocardial-infarction remodelling, and a preservation of kidney function in the presence of diabetic nephropathy, in hypertensive patients taking candesartan cilexetil.
Preclinical and early clinical studies of the leading group of AIIRAs that are currently available or at advanced stages of development have been performed to explore the impact of the distinct differences in mode of action from ACE inhibitors, particularly with regard to their clinical benefits in terms of ACEinhibitor-associated cough 10 and angioneurotic oedema. 11 As predicted, the lack of bradykinin potentiation with AIIRA does indeed translate into placebolike levels of these troublesome adverse effects. However, as our experience of using AIIRAs in the clinic grows it is also increasingly apparent that individual compounds display significant differences in their pharmacology and clinical behaviour within the AIIRA class, which should be taken into account by physicians when selecting the most appropriate treatment. In particular, AIIRAs have marked differences in their binding characteristics at AT 1 receptors. To what extent these differences may be reflected in vivo remain uncertain. Candesartan has a much greater affinity for AT 1 receptors than does losartan, the first non-peptide AIIRA introduced. In in vitro studies, candesartan cilexetil is highly selective for the AT 1 receptor subtype and exhibits tight binding, as well as slow dissociation from the receptor. 12 In similar in vitro studies, losartan is a competitive or surmountable antagonist with angiotensin II at the AT 1 receptor, whereas candesartan cilexetil distinctly acts as an insurmountable antagonist. The active losartan metabolite EXP 3174 in this model acts as a mixed antagonist. The observations are not easily reproduced in in vivo studies and to what extent they relate to differences in apparent clinical efficacy and duration of action of these drugs remain at present conjectural.
Duration of action
A key efficacy criterion of choice of any given antihypertensive agent is the degree to which these blood pressure-lowering effects are maintained throughout the 24-h period. Although sophisticated measures of the 24-h profiles of antihypertensive drugs are being developed (Mancia G et al, unpublished data), a widely recognised parameter is the simple trough:peak blood pressure ratio. On this basis, candesartan cilexetil demonstrates an excellent 24-h blood pressure profile, with a trough:peak ratio close to unity. 13 This compares favourably with lower trough:peak values for losartan and other AIIRAs. The prolonged antihypertensive activity of candesartan cilexetil is likely related to its specific binding characteristics to the AT 1 receptor at the tissue level.
14 Dr Inada's group, of Pharmaceutical Research, Takeda Chemical Industries Ltd, Osaka, Japan, report in this supplement on potent and long-lasting antihypertensive effects of candesartan cilexetil in clinical trials and in several animal models of hypertension. They confirm that the insurmountable antagonism of candesartan cilexetil in vascular contraction is likely the result of its tight binding and slow dissociation from angiotensin II AT 1 receptors.
In a 12-month study, 15 mean sitting diastolic blood pressure was progressively reduced from approximately 100 mm Hg at baseline to approximately 85 mm Hg with candesartan cilexetil, and a response rate of more than 80% was achieved ( Figure 1 ). These data indicate that candesartan cilexetil is effective in a large proportion of hypertensive patients and that blood pressure response is maintained long-term.
Time-to-effect relationship
In a report by the author and colleagues, which was summarised in a poster session at the proceedings, a total of 1187 patients received 8 or 16 mg of candesartan cilexetil or placebo once daily for 4 to 12 weeks. The results of a meta-analysis showed that approximately two-thirds of the total reduction in blood pressure seen at 8 weeks with candesartan cilexetil is achieved within 1 week of starting therapy, with 80% of the effect evident after 2 weeks and about 90% after 4 weeks (Sever et al, unpublished data) (Figure 2 ). There was no evidence of orthostatic hypotension. These results equally relate to diastolic blood pressure and to systolic blood pressure and to all dose levels.
Antihypertensive efficacy of candesartan in clinical trials
A number of randomised, placebo-controlled clinical trials have demonstrated that, over the full dose range of 4 to 16 mg once daily, candesartan cilexetil produces an impressive and distinctive dose-dependent reduction in both systolic and diastolic blood pressure. 16 This body of clinical evidence compares favourably with clinical experience gained with some other AIIRAs. Losartan and valsartan, for example, display a flat dose-response relationship in their blood pressure-lowering effects, 17, 18 while for irbesartan there appears to be a dose-response relationship in patients with mild to moderate hypertension. 19 A meta-analysis of six large, placebocontrolled, randomised studies ( Figure 3 ) clearly illustrates the dose-response relationship of candesartan cilexetil given in doses from 4 -16 mg once daily. 16 Clinical trials have also shown that the magnitude of blood pressure lowering with candesartan cilexetil is at least equivalent to that of several widely used antihypertensive agents, including the ACE inhibitor enalapril, the calcium antagonist amlodipine, and the diuretic hydrochlorothiazide. [20] [21] [22] [23] [24] The additional lowering of blood pressure that is possible with combined regimens of candesartan cilexetil with hydrochlorothiazide [23] [24] [25] and amlodipine 22 has also been confirmed by several studies.
The antihypertensive efficacy of candesartan cilexetil in patients with moderate to severe hypertension was investigated in a multicentre, doubleblind study. 25 Patients received candesartan cilexetil titrated according to response from 8 to 16 mg once daily, with sequential addition of amlodipine 5 mg and hydrochlorothiazide 25 mg once daily at set intervals. An overall response rate of 82% was achieved after 12 weeks' treatment with candesartan cilexetil monotherapy or add-on therapy.
Also included in this supplement is a review by Dr Ogihara's group at the Department of Geriatric Medicine, Osaka University, and the Department of Medicine, School of Medicine, Fukuoka University, Japan, of results of Japanese clinical trials of candesartan cilexetil. They found that, in 14 multicentre studies, low dose candesartan cilexetil (2-8 mg once daily) had an efficacy rate of 72% and 63%, and a reported overall low adverse event rate of 9.9% and 7.3%, in patients with mild-to-moderate essential hypertension and those with impaired renal function, respectively. Elderly patients enjoyed the same efficacy and tolerability as younger patients. In a double-blind comparative study, candesartan cilexetil was superior to enalapril in hypertensive patients. Daily treatment of candesartan cilexetil for 8 to 12 weeks reduced the left ventricular mass index without deterioration of cardiac function in patients with hypertension. 
Comparative antihypertensive efficacy of candesartan and other AIIRAs
The intrinsic blood pressure-lowering efficacy of new antihypertensive agents is an important factor to consider when selecting the most suitable treatment for a particular patient group. A direct comparison of the efficacy of standard once-daily doses of candesartan cilexetil (8 mg and 16 mg/day) and losartan (50 mg/day) by Andersson et al 13 found a significant (P = 0.013) difference in blood pressure reduction with the two agents (Figure 4) . The reduction in mean diastolic blood pressure with candesartan cilexetil (16 mg) was more than 50% greater than that achieved with losartan (50 mg) although there was no comparison in this study with higher doses of losartan.
Mechanism of action
The mechanism underlying the greater antihypertensive efficacy of candesartan cilexetil over losartan and other AIIRAs is as yet unknown. It is perhaps related to more complete AT 1 -receptor blockade as suggested by the greater reactive rise in plasma renin activity observed in salt-replete, normotensive sub- Figure 4 Changes in mean diastolic blood pressure with candesartan cilexetil 8 mg and 16 mg once-daily, compared with losartan 50 mg once-daily and placebo, showing the superior clinical efficacy of candesartan cilexetil. 13 jects with candesartan cilexetil, compared with an equivalent dose of losartan. 31 Another factor to consider is that losartan achieves most of its antihypertensive activity from an active carboxylic acid metabolite, EXP 3174, via the action of hepatic microsomal enzymes. 26 On average, only 14% of losartan is converted in this way to EXP 3174. Candesartan cilexetil is completely hydrolysed to the active moiety, candesartan, during gastrointestinal absorption. Moreover, peak plasma concentrations of EXP 3174 exhibit wide intersubject variations, suggesting widespread differences in hepatic metabolism of losartan in a given patient population.
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Safety profile
As a class, AIIRAs have demonstrated a favourable safety and tolerability profile compared with other classes of antihypertensives, including ACE inhibitors and calcium antagonists. Candesartan follows this trend and displays a similar tolerability profile to placebo over its full dose range. Candesartan is equally well tolerated by men and women, and by elderly and younger patients. 
Tolerability
The typically asymptomatic nature of hypertension, coupled with its long-term course and link to cardiovascular morbidity and mortality, means that the tolerability profile of antihypertensive therapy is particularly important. Poor tolerability leads to noncompliance and treatment failure. One of the most remarkable features of the AIIRA class generally, and candesartan cilexetil in particular, is the tolerability profile virtually indistinguishable from that of placebo. This is illustrated by Figure 5 , which shows the incidence of the six most common adverse events reported by healthy volunteers and hypertensive patients treated with candesartan cilexetil or placebo. 27 There were no significant differences in the occurrence of these adverse events between the two groups, regardless of age, gender or dose.
Candesartan cilexetil is virtually devoid of the troublesome cough typically associated with ACEinhibitor therapy. In a placebo-controlled comparative study, the incidence of adverse events with candesartan cilexetil (11.3%) was considerably lower than that with enalapril (23.5%), and lower than that found in the placebo group (15.9%). 21 Enalapriltreated patients also experienced a higher incidence of cough and withdrawal due to adverse events than Figure 6 Thickening of the carotid artery intima in vitro induced by endothelial damage (balloon catheter) with and without candesartan cilexetil, 10 mg/kg per day for 2 weeks, demonstrating its vasoprotective properties. did patients treated with candesartan cilexetil (3.7% vs 0%).
Moreover, there is no indication that doses of candesartan cilexetil higher than the clinically relevant dose range has any marked effect on tolerability. The absence of a dose-response relationship for adverse events with candesartan cilexetil may be relevant for end-organ protection. Candesartan appears to be devoid of either orthostatic hypotension or first-dose hypotension, and there have been no reports of rebound hypertension after cessation of treatment.
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Effect of candesartan on insulin sensitivity
There is no evidence of adverse effects on serum lipid profile or glucose homeostasis in a 12-week trial of once-daily treatment with candesartan cilexetil in patients with hypertension and type II diabetes. 29 Indeed, candesartan cilexetil is reported to improve insulin sensitivity in patients with essential hypertension. Dr Higashiura and colleagues from the Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, report in this supplement on the effect of candesartan cilexetil on sodium-retaining action and the activation of pressor systems by hyperinsulinaemia, which might be related to pressor mechanisms in essential hypertension. Candesartan cilexetil restored insulin sensitivity in patients with essential hypertension to the level of that in normotensive subjects. In addition, the sodium-retaining action of hyperinsulinaemia was attenuated by treatment with candesartan cilexetil.
End-organ protection
AIIRAs may confer advantages over ACE inhibitors with regard to end-organ protection (heart, vasculature, brain, and kidneys). These effects may be partly related to or wholly independent of blood pressurelowering effects. Not surprisingly, most available evidence at present is derived from experimental animal models; clinical data are very limited, to date.
Cardiac and vascular system:
In an excellent review of the effect of antihypertensive agents on cardiac and vascular remodelling published in this supplement, Dr Mallion and colleagues of the Medecine Interne et Cardiologie, Grenoble Cedex, France, discuss the clinical implications of cardiac changes, the cause of structural changes, the distinction between left ventricular mass and vascular hypertrophy, and the role of reference values and vascular vs cardiac indices in the clinical management of hypertension.
Regression of vascular hypertrophy with AIIRA and ACE inhibitor therapy has been demonstrated in an animal model. In an in vivo study reported in this supplement, Tsutomu Yamazaki and Yoshio Yazaki, of the Department of Cardiovascular Medicine, Faculty of Medicine, and the Health Service Centre, the University of Tokyo, treated spontaneously hypertensive rats with candesartan cilexetil or hydralazine.
39 Untreated rats progressively developed severe hypertension, and treatment with candesartan cilexetil or hydralazine decreased blood pressure. Candesartan cilexetil reduced left ventricular weight and wall thickness, transverse myocyte diameter, the relative amount of V3 myosin heavy chain, and interstitial fibrosis, while treatment with hydralazine slightly prevented an increase in left ventricular wall thickness, but produced no significant reduction in the other parameters. In an in vitro study by the same authors, pretreatment with candesartan cilexetil diminished an increase in phenylalanine incorporation, MAP kinase activity, and c-fos gene expression induced by the stretching of neonatal rat cardiomyocytes. They also found that angiotensin II-evoked signal transduction pathways differed between cell types. In cardiac fibroblasts, angiotensin II activated MAP kinase through a pathway including the G␤␥ subunit of Gi protein, Src, Shc, Grb2, and Ras, while Gq and protein kinase C were important in cardiac myocytes. In another study, candesartan cilexetil and enalapril both exhibited protective effects in an ischaemic model with myocardial fibrosis as the end-point, but no effects were seen with a non-selective vasodilator.
The roles of angiotensin II as produced by two different enzymes, ACE and chymase, were investigated by Dr Miyazaki and coworkers at the Department of Pharmacology, Osaka Medical College, Takatsuki, Japan, and the Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, Japan. In their study published in this supplement, they administered oral candesartan cilexetil or enalapril to dogs twice daily for 5 weeks. After 1 week of active drug therapy, the common carotid and femoral arteries were unilaterally injured by balloon catheterization. The authors found that candesartan cilexetil significantly suppressed the formation of intima hyperplasia in both the carotid and femoral arteries, while enalapril significantly suppressed intima hyperplasia in the femoral, but not in the carotid, arteries. These results indicate that local angiotensin II production by ACE and chymase is involved in the hyperplasia seen in injured intima, and the difference in the inhibitory action of candesartan cilexetil and enalapril reflects the extent of contribution of each enzyme. That is, the effect of enalapril depended on the activity of ACE, whereas that of candesartan cilexetil was independent of ACE activity. Similar studies in which thickening of the carotid artery intima was induced by endothelial injury have demonstrated that administration of candesartan cilexetil has a protective action on vasculature ( Figure 6 ).
Brain: Perhaps one of the most exciting areas of future development for AIIRAs such as candesartan cilexetil is in protection against stroke, as already studied in spontaneously hypertensive stroke-prone rats. In this model, higher doses of candesartan cilexetil reduced blood pressure, as well as the incidence of stroke, compared with untreated controls. 30 Interestingly, doses of candesartan cilexetil that have little or no effect on blood pressure also significantly reduced the incidence of stroke. Extrapolating these findings to the clinical setting raises the prospect of developing interventional therapies with the capacity to protect normotensive individuals from vascular disease and stroke.
Kidney:
The selective blockade of AT 1 -receptors leaves the AT 2 receptors exposed to elevated levels of endogenous angiotensin II. According to a report in this supplement by Professor Kiyoshi Kurokawa, Dean of the First Department of Internal Medicine, School of Medicine, Tokai University, Japan, this may be an advantage of AT 1 -receptor blockade over ACE inhibition in the management of a variety of chronic vascular diseases, including chronic glomerulonephritis and other glomerular diseases. In a clinical trial, candesartan cilexetil effectively lowered urinary protein excretion in patients with chronic glomerulonephritis. This beneficial effect on protein excretion was independent of the effect on systemic blood pressure, which was normal in the majority of patients studied.
Dr Maarten W Taal and Dr Barry M Brenner of the Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, review, in this supplement, studies that have compared the effects of standard doses of ACE-I and AIIRAs in several rat models of chronic renal disease. Most studies found similar beneficial effects, including amelioration of proteinuria and glomerulosclerosis for renal diseases such as passive Heymann nephritis, hypertensive nephrosclerosis, diabetic nephropathy, and progressive glomerulosclerosis secondary to reduced renal mass.
Dr Sugimoto and coworkers at the Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan, investigated the influence of candesartan cilexetil and enalapril on the oxidative state of renal tissue and renal function in 5/6 nephrectomized rats. In their report, published in this supplement, they found that while both drugs significantly blunted the rise in urinary protein, neither candesartan cilexetil nor enalapril affected antioxidant defences in renal tissue in nephrectomized rats, indicating that mechanisms other than alteration in oxidative stress are involved in the renoprotective effects of candesartan cilexetil and enalapril.
One long-term study has shown greater inhibition of glomerulosclerosis, interstitial fibrosis, and TGF-␤ synthesis in rats treated with candesartan cilexetil than in those treated with enalapril after renal mass reduction. However, conclusions regarding the relative efficacy of these two groups of agents in ameliorating the progression of chronic renal disease await the results of further long-term studies.
Summary
This supplement reflects the current status of research into AIIRAs in general, and candesartan cilexetil, in particular. According to the selection criteria presented herein, candesartan cilexetil would appear to possess many of the features of an ideal antihypertensive agent. Dose-dependent and effective blood pressure reduction is accompanied by a 24-h profile of sustained activity that is ideally suited to once-daily administration. Candesartan cilexetil has a tolerability profile at all dose levels that is indistinguishable from placebo and displays protective effects for key target organs. This recent addition to the arsenal of cardiovascular therapeutics is clearly eminently qualified as first-line therapy for hypertension in a wide variety of patients, both as monotherapy and in combination. As clinical experience with candesartan cilexetil and other AIIRAs grows, so do the future prospects for greater and more diverse improvements in morbidity and mortality for patients with hypertension and other cardiovascular disease. In addition, we will likely learn more about the differences between the various AIIRAs currently in clinical use.
